Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda’s Alogliptin Falls Prey To FDA Slowdown

This article was originally published in The Pink Sheet Daily

Executive Summary

Delay is no bellwether for oral anti-diabetic drugs, the firm says.

You may also be interested in...



FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin

FDA may be heeding stakeholder calls to set new action dates once an original user fee deadline is missed.

FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin

FDA may be heeding stakeholder calls to set new action dates once an original user fee deadline is missed.

Takeda Faces Serial FDA Delays, Yen Appreciation And Acquisition Drags In 2008

Japanese firm incurs “income contraction” for the first time in 17 years.

Related Content

Topics

UsernamePublicRestriction

Register

PS066869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel